[{"address1": "2929 7th Street", "address2": "Suite 105", "city": "Berkeley", "state": "CA", "zip": "94710", "country": "United States", "phone": "510 982 6030", "website": "https://cariboubio.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Caribou Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of genome-edited allogeneic cell therapies for the treatment of hematologic malignancies in the United States and internationally. Its lead product candidate is CB-010, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1 clinical trial to treat relapsed or refractory B cell non-Hodgkin lymphoma. The company also develops CB-011, an allogeneic anti-BCMA CAR-T cell therapy that is in phase 1 clinical trial for the treatment of relapsed or refractory multiple myeloma; and CB-012, an allogeneic anti-CD371 CAR-T cell therapy that is in phase 1 clinical trial for the treatment of relapsed or refractory acute myeloid leukemia. Caribou Biosciences, Inc. was incorporated in 2011 and is headquartered in Berkeley, California.", "fullTimeEmployees": 158, "auditRisk": 7, "boardRisk": 5, "compensationRisk": 8, "shareHolderRightsRisk": 8, "overallRisk": 7, "governanceEpochDate": 1717200000, "maxAge": 86400, "priceHint": 4, "previousClose": 1.72, "open": 1.73, "dayLow": 1.67, "dayHigh": 1.79, "regularMarketPreviousClose": 1.72, "regularMarketOpen": 1.73, "regularMarketDayLow": 1.67, "regularMarketDayHigh": 1.79, "beta": 2.426, "forwardPE": -0.8229666, "volume": 8386140, "regularMarketVolume": 8386140, "averageVolume": 2326304, "averageVolume10days": 3572180, "averageDailyVolume10Day": 3572180, "bid": 1.69, "ask": 1.72, "bidSize": 1700, "askSize": 1600, "marketCap": 155346624, "fiftyTwoWeekLow": 1.6, "fiftyTwoWeekHigh": 8.59, "priceToSalesTrailing12Months": 4.6505394, "fiftyDayAverage": 3.1204, "twoHundredDayAverage": 4.88975, "currency": "USD", "enterpriseValue": -111482432, "floatShares": 69029872, "sharesOutstanding": 90317800, "sharesShort": 10485832, "sharesShortPriorMonth": 11342625, "sharesShortPreviousMonthDate": 1713139200, "dateShortInterest": 1715731200, "sharesPercentSharesOut": 0.1161, "heldPercentInsiders": 0.10057, "heldPercentInstitutions": 0.7698, "shortRatio": 6.52, "shortPercentOfFloat": 0.121700004, "impliedSharesOutstanding": 90317800, "bookValue": 3.801, "priceToBook": 0.4525125, "lastFiscalYearEnd": 1703980800, "nextFiscalYearEnd": 1735603200, "mostRecentQuarter": 1711843200, "netIncomeToCommon": -115260000, "trailingEps": -1.38, "forwardEps": -2.09, "pegRatio": -0.06, "enterpriseToRevenue": -3.337, "enterpriseToEbitda": 0.876, "52WeekChange": -0.57843137, "SandP52WeekChange": 0.26238096, "exchange": "NMS", "quoteType": "EQUITY", "symbol": "CRBU", "underlyingSymbol": "CRBU", "shortName": "Caribou Biosciences, Inc.", "longName": "Caribou Biosciences, Inc.", "firstTradeDateEpochUtc": 1627047000, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EDT", "uuid": "f11f6be1-a9a3-3c9c-bdb1-a1f42c197bdb", "messageBoardId": "finmb_272189231", "gmtOffSetMilliseconds": -14400000, "currentPrice": 1.72, "targetHighPrice": 30.0, "targetLowPrice": 9.0, "targetMeanPrice": 17.88, "targetMedianPrice": 18.0, "recommendationMean": 1.8, "recommendationKey": "buy", "numberOfAnalystOpinions": 8, "totalCash": 293988000, "totalCashPerShare": 3.255, "ebitda": -127299000, "totalDebt": 27159000, "quickRatio": 10.255, "currentRatio": 10.493, "totalRevenue": 33404000, "debtToEquity": 7.911, "revenuePerShare": 0.413, "returnOnAssets": -0.21700001, "returnOnEquity": -0.37087002, "freeCashflow": -74012624, "operatingCashflow": -102555000, "revenueGrowth": -0.306, "grossMargins": -2.59699, "operatingMargins": -18.93866, "financialCurrency": "USD", "trailingPegRatio": null, "__fetch_time": "2024-06-24"}]